EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients

Simón A. Ojeda-Duran, Iván Lyra-Gonzalez, Alejandra Meza-Rios, Silvia Lucano-Landeros, Ana Sandoval-Rodriguez, Monica Vazquez-Del Mercado, Arturo Santos, Lucia Flores-Contreras, Juan Armendáriz-Borunda

Journal of Renal and Hepatic Disorders · 2020

DOI: 10.15586/jrenhep.2020.61 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Renal and Hepatic Disorders, 2020. Verfasst von Simón A. Ojeda-Duran und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this pilot clinical trial was to evaluate the safety of a new formulation of prolonged-release Pirfenidone (PR-PFD) in chronic kidney disease (CKD), specifically focal and segmental glomerular hyalinization (FSGH). Open-label, pilot, nonrandomized trial. Eighteen patients previously diagnosed with CKD stages 1– 5 according to “Kidney Disease: Improving Global Outcomes” were enrolled in the study. Target dos-age of PFD was 1200 mg twice a day in the form of prolonged-release tablets to reach a full dosage of 2400 mg daily. Clinical trial was carried out for 60 months to evaluate the safety and efficacy of a newly formulated PR-PFD in patients with CKD. After the treatment for 60 months, it was found that PR-PFD kept renal function from declining significantly in CKD patients, as the glomerular filtration rate (GFR) showed only minimal variations throughout the study. Estimated glomerular filtration rate (eGFR) showed no differences at both baseline and the end points. Proteinuria improved, and creatinine, cystatin C, urea, hemoglobin and hepatic transaminases remained constant without any considerable changes across the study. Minor side effects were noticed when compared with those found in previous studies, indicating an increased tolerance to this pharmaceutical formulation of PFD. Prolonged-released PFD could be safely used as an adjuvant therapy in patients with CKD.Registry number was obtained from ClinicalTrials.gov (NCT02408744).

Zitieren

APA

Ojeda-Duran, S. A., Lyra-Gonzalez, I., Meza-Rios, A., Lucano-Landeros, S., Sandoval-Rodriguez, A., Mercado, M. V., Santos, A., Flores-Contreras, L., & Armendáriz-Borunda, J. (2020). Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients. Journal of Renal and Hepatic Disorders. https://doi.org/10.15586/jrenhep.2020.61

Vancouver

Ojeda-Duran SA, Lyra-Gonzalez I, Meza-Rios A, Lucano-Landeros S, Sandoval-Rodriguez A, Mercado MV, et al. Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients. Journal of Renal and Hepatic Disorders. 2020. doi:10.15586/jrenhep.2020.61

BibTeX
@article{OjedaDuran2020,
  author = {Ojeda-Duran, Simón A. and Lyra-Gonzalez, Iván and Meza-Rios, Alejandra and Lucano-Landeros, Silvia and Sandoval-Rodriguez, Ana and Mercado, Monica Vazquez-Del and Santos, Arturo and Flores-Contreras, Lucia and Armendáriz-Borunda, Juan},
  title = {Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients},
  journal = {Journal of Renal and Hepatic Disorders},
  year = {2020},
  doi = {10.15586/jrenhep.2020.61}
}
Kostenlos starten →